The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Tejedor Vaquero, Sonia, 1988-
• dc.contributor.author Campos Mata, Leire de, 1991-
• dc.contributor.author Ramada Rodilla, José María, 1961-
• dc.contributor.author Díaz, Pilar
• dc.contributor.author Navarro-Barriuso, Juan
• dc.contributor.author Ribas-Llauradó, Clara
• dc.contributor.author Rodrigo Melero, Natalia
• dc.contributor.author Carolis, Carlo
• dc.contributor.author Cerutti, Andrea, 1965-
• dc.contributor.author Gimeno Martínez, Ramón
• dc.contributor.author Magri, Giuliana, 1978-
• dc.date.accessioned 2022-01-19T12:29:42Z
• dc.date.available 2022-01-19T12:29:42Z
• dc.date.issued 2021
• dc.description.abstract mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen.
• dc.description.sponsorship This study was supported by the COVID-19 call grant from Generalitat de Catalunya, Department of Health (to GM), grant Miguel Servet research program (to GM) and by National Health Institute Carlos III (ISCIII) through the project COV20_00508 grant (Co-funded by European Regional Development Fund/European Social Fund “a way to make Europe) (to RG)
• dc.format.mimetype application/pdf
• dc.identifier.citation Tejedor Vaquero S, de Campos-Mata L, Ramada JM, Díaz P, Navarro-Barriuso J, Ribas-Llaurado C et al. The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity. Front Immunol. 2021;12:737083. DOI: 10.3389/fimmu.2021.737083
• dc.identifier.doi http://dx.doi.org/10.3389/fimmu.2021.737083
• dc.identifier.issn 1664-3224
• dc.identifier.uri http://hdl.handle.net/10230/52261
• dc.language.iso eng
• dc.publisher Frontiers Media
• dc.relation.ispartof Frontiers in Immunology. 2021;12:737083.
• dc.rights © 2021 Sonia Tejedor Vaquero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/4.0/
• dc.subject.other COVID-19 (Malaltia)
• dc.subject.other Vacunació
• dc.subject.other Immunitat
• dc.title The mRNA-1273 vaccine induces cross-variant antibody responses to SARS-CoV-2 with distinct profiles in individuals with or without pre-existing immunity
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion